Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Total Current Liabilities (2022 - 2025)

Axsome Therapeutics' Total Current Liabilities history spans 4 years, with the latest figure at $378.8 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 64.64% year-over-year to $378.8 million; the TTM value through Dec 2025 reached $378.8 million, up 64.64%, while the annual FY2025 figure was $378.8 million, 64.64% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $378.8 million at Axsome Therapeutics, up from $360.3 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $378.8 million in Q4 2025 and bottomed at $24.5 million in Q1 2022.
  • The 4-year median for Total Current Liabilities is $141.5 million (2023), against an average of $173.4 million.
  • The largest annual shift saw Total Current Liabilities surged 309.99% in 2023 before it soared 43.11% in 2024.
  • A 4-year view of Total Current Liabilities shows it stood at $96.6 million in 2022, then surged by 43.8% to $138.9 million in 2023, then surged by 65.72% to $230.1 million in 2024, then soared by 64.64% to $378.8 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Total Current Liabilities are $378.8 million (Q4 2025), $360.3 million (Q3 2025), and $342.1 million (Q2 2025).